Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
NewAmsterdam Pharma Company N.V. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
NAMS
Nasdaq
2836
www.newamsterdampharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
- Jan 29th, 2025 1:00 pm
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
- Jan 10th, 2025 1:00 pm
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Jan 9th, 2025 8:38 pm
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- Dec 13th, 2024 10:16 pm
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
- Dec 12th, 2024 2:37 am
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
- Dec 11th, 2024 8:06 pm
NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug
- Dec 10th, 2024 10:10 pm
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
- Dec 10th, 2024 9:34 pm
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
- Dec 10th, 2024 12:00 pm
NewAmsterdam Pharma Reports Promising Phase 3 Trial Results
- Nov 21st, 2024 12:37 pm
NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study
- Nov 20th, 2024 9:13 pm
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
- Nov 20th, 2024 12:00 pm
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
- Nov 18th, 2024 8:20 pm
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Could Be 46% Below Their Intrinsic Value Estimate
- Nov 11th, 2024 10:43 am
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
- Nov 6th, 2024 1:00 pm
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
- Oct 28th, 2024 8:30 pm
Three Undervalued Small Caps In United States With Insider Buying To Consider
- Oct 8th, 2024 11:01 am
Insider Buying Highlights These 3 Undervalued Small Caps In United States
- Oct 7th, 2024 11:03 am
3 Undervalued Small Caps In United States With Insider Buying
- Oct 1st, 2024 11:02 am
While institutions own 29% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), private equity firms are its largest shareholders with 47% ownership
- Sep 7th, 2024 12:18 pm
Scroll